Search

Your search keyword '"Tariot, Pierre N."' showing total 1,027 results
Start Over Author "Tariot, Pierre N."
1,027 results on '"Tariot, Pierre N."'

1. Impact of APOE ε4 and ε2 on plasma neurofilament light chain and cognition in autosomal dominant Alzheimer’s disease

Author

Langella, Stephanie, Bonta, Kyra, Chen, Yinghua, Su, Yi, Vasquez, Daniel, Aguillon, David, Acosta-Baena, Natalia, Baena, Ana Y., Garcia-Ospina, Gloria, Giraldo-Chica, Margarita, Tirado, Victoria, Muñoz, Claudia, Ríos-Romenets, Silvia, Guzman-Martínez, Claudia, Pruzin, Jeremy J., Ghisays, Valentina, Arboleda-Velasquez, Joseph F., Kosik, Kenneth S., Tariot, Pierre N., Reiman, Eric M., Lopera, Francisco, and Quiroz, Yakeel T.

Published
2024
Full Text
View/download PDF

5. Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report.

Author

Arboleda-Velasquez, Joseph F, Lopera, Francisco, O'Hare, Michael, Delgado-Tirado, Santiago, Marino, Claudia, Chmielewska, Natalia, Saez-Torres, Kahira L, Amarnani, Dhanesh, Schultz, Aaron P, Sperling, Reisa A, Leyton-Cifuentes, David, Chen, Kewei, Baena, Ana, Aguillon, David, Rios-Romenets, Silvia, Giraldo, Margarita, Guzmán-Vélez, Edmarie, Norton, Daniel J, Pardilla-Delgado, Enmanuelle, Artola, Arabiye, Sanchez, Justin S, Acosta-Uribe, Juliana, Lalli, Matthew, Kosik, Kenneth S, Huentelman, Matthew J, Zetterberg, Henrik, Blennow, Kaj, Reiman, Rebecca A, Luo, Ji, Chen, Yinghua, Thiyyagura, Pradeep, Su, Yi, Jun, Gyungah R, Naymik, Marcus, Gai, Xiaowu, Bootwalla, Moiz, Ji, Jianling, Shen, Lishuang, Miller, John B, Kim, Leo A, Tariot, Pierre N, Johnson, Keith A, Reiman, Eric M, and Quiroz, Yakeel T

Subjects
Brain, Humans, Alzheimer Disease, Neurodegenerative Diseases, Amyloid, Pedigree, Homozygote, Mutation, Aged, Female, Male, Apolipoprotein E2, Apolipoprotein E3, Presenilin-1, Cognitive Dysfunction, Immunology, Medical and Health Sciences
Abstract

We identified a PSEN1 (presenilin 1) mutation carrier from the world's largest autosomal dominant Alzheimer's disease kindred, who did not develop mild cognitive impairment until her seventies, three decades after the expected age of clinical onset. The individual had two copies of the APOE3 Christchurch (R136S) mutation, unusually high brain amyloid levels and limited tau and neurodegenerative measurements. Our findings have implications for the role of APOE in the pathogenesis, treatment and prevention of Alzheimer's disease.

Published
2019

7. Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Prevention Initiative (API) Generation Studies.

Author

Tariot, Pierre N., Riviere, Marie‐Emmanuelle, Salloway, Stephen, Burns, Jeffrey M., Snaedal, Jón G., Borowsky, Beth, Lopez, Cristina Lopez, Liu, Fonda, Rouzade‐Dominguez, Marie‐Laure, Cazorla, Pilar, Mousseau, Marie‐Catherine, Arkuszewski, Michal, Ricart, Javier, Viglietta, Vissia, Sui, Yihan, Caputo, Angelika, Langbaum, Jessica B., Reiman, Eric M., and Graf, Ana

Abstract

INTRODUCTION: The Alzheimer's Prevention Initiative (API) Generation Studies evaluated the BACE inhibitor umibecestat for Alzheimer's disease (AD) prevention. The studies were terminated early, and the reversibility of umibecestat's side effects was assessed. METHODS: Cognitively unimpaired 60‐ to 75‐year‐old apolipoprotein E (APOE) ε4 homozygotes and heterozygotes (the latter with elevated brain amyloid deposition) (n = 1556) received umibecestat (50 or 15 mg daily) or placebo for 7 months on average and were followed for a median (interquartile range) of 4 (3 to 6) months after washout. RESULTS: Compared to placebo, umibecestat‐treated participants had small, non‐progressive, but statistically significant decline in performance on certain cognitive batteries including Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and API Preclinical Composite Cognitive test, but not Clinical Dementia Rating‐Sum of Boxes. RBANS differences were no longer significant at the end of follow‐up. DISCUSSION: In people at genetic risk for AD, high‐dose beta‐site amyloid precursor protein cleaving enzyme (BACE) inhibition was associated with early mild cognitive worsening, which reversed shortly after washout, suggesting a symptomatic side effect not associated with neurodegeneration. Fully anonymized data, images, and samples are available upon request for further research on BACE inhibition. Highlights: This is the first trial with blinded assessment of reversibility of BACE inhibitor side effects.Umibecestat was tested in cognitively unimpaired persons at genetic risk for AD.Umibecestat led to early mild cognitive decline that reversed shortly after washout.This suggests a potentially manageable effect not associated with neurodegeneration.Further research may determine the future of BACE inhibition in AD prevention. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts.

Author

Qian, Jing, Wolters, Frank J, Beiser, Alexa, Haan, Mary, Ikram, M Arfan, Karlawish, Jason, Langbaum, Jessica B, Neuhaus, John M, Reiman, Eric M, Roberts, J Scott, Seshadri, Sudha, Tariot, Pierre N, Woods, Beth McCarty, Betensky, Rebecca A, and Blacker, Deborah

Subjects
Humans, Dementia, Apolipoproteins E, Risk Factors, Cohort Studies, Gene Frequency, Genotype, Aged, Middle Aged, United States, Netherlands, Female, Male, Cognitive Dysfunction, General & Internal Medicine, Medical and Health Sciences
Abstract

BackgroundWith the onset of prevention trials for individuals at high risk for Alzheimer disease, there is increasing need for accurate risk prediction to inform study design and enrollment, but available risk estimates are limited. We developed risk estimates for the incidence of mild cognitive impairment (MCI) or dementia among cognitively unimpaired individuals by APOE-e4 dose for the genetic disclosure process of the Alzheimer's Prevention Initiative Generation Study, a prevention trial in cognitively unimpaired APOE-e4/e4 homozygote individuals.Methods and findingsWe included cognitively unimpaired individuals aged 60-75 y, consistent with Generation Study eligibility criteria, from the National Alzheimer's Coordinating Center (NACC) (n = 5,073, 158 APOE-e4/e4), the Rotterdam Study (n = 6,399, 156 APOE-e4/e4), the Framingham Heart Study (n = 4,078, 67 APOE-e4/e4), and the Sacramento Area Latino Study on Aging (SALSA) (n = 1,294, 11 APOE-e4/e4). We computed stratified cumulative incidence curves by age (60-64, 65-69, 70-75 y) and APOE-e4 dose, adjusting for the competing risk of mortality, and determined risk of MCI and/or dementia by genotype and baseline age. We also used subdistribution hazard regression to model relative hazard based on age, APOE genotype, sex, education, family history of dementia, vascular risk, subjective memory concerns, and baseline cognitive performance. The four cohorts varied considerably in age, education, ethnicity/race, and APOE-e4 allele frequency. Overall, cumulative incidence was uniformly higher in NACC than in the population-based cohorts. Among APOE-e4/e4 individuals, 5-y cumulative incidence was as follows: in the 60-64-y age stratum, it ranged from 0% to 5.88% in the three population-based cohorts versus 23.06% in NACC; in the 65-69-y age stratum, from 9.42% to 10.39% versus 34.62%; and in the 70-75-y age stratum, from 18.64% to 33.33% versus 38.34%. Five-year incidence of dementia was negligible except for APOE-e4/e4 individuals and those over 70 y. Lifetime incidence (to age 80-85 y) of MCI or dementia for the APOE-e4/e4 individuals in the long-term Framingham and Rotterdam cohorts was 34.69%-38.45% at age 60-64 y, 30.76%-40.26% at 65-69 y, and 33.3%-35.17% at 70-75 y. Confidence limits for these estimates are often wide, particularly for APOE-e4/e4 individuals and for the dementia outcome at 5 y. In regression models, APOE-e4 dose and age both consistently increased risk, as did lower education, subjective memory concerns, poorer baseline cognitive performance, and family history of dementia. We discuss several limitations of the study, including the small numbers of APOE-e4/e4 individuals, missing data and differential dropout, limited ethnic and racial diversity, and differences in definitions of exposure and outcome variables.ConclusionsEstimates of the absolute risk of MCI or dementia, particularly over short time intervals, are sensitive to sampling and a variety of methodological factors. Nonetheless, such estimates were fairly consistent across the population-based cohorts, and lower than those from a convenience cohort and those estimated in prior studies-with implications for informed consent and design for clinical trials targeting high-risk individuals.

Published
2017

10. Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study

Author

Quiroz, Yakeel T, Zetterberg, Henrik, Reiman, Eric M, Chen, Yinghua, Su, Yi, Fox-Fuller, Joshua T, Garcia, Gloria, Villegas, Andres, Sepulveda-Falla, Diego, Villada, Marina, Arboleda-Velasquez, Joseph F, Guzmán-Vélez, Edmarie, Vila-Castelar, Clara, Gordon, Brian A, Schultz, Stephanie A, Protas, Hillary D, Ghisays, Valentina, Giraldo, Margarita, Tirado, Victoria, Baena, Ana, Munoz, Claudia, Rios-Romenets, Silvia, Tariot, Pierre N, Blennow, Kaj, and Lopera, Francisco

Published
2020
Full Text
View/download PDF

12. Homozygosity of the autosomal dominant Alzheimer disease presenilin 1 E280A mutation

Author

Kosik, Kenneth S, Muñoz, Claudia, Lopez, Liliana, Arcila, Mary Luz, García, Gloria, Madrigal, Lucía, Moreno, Sonia, Ríos Romenets, Silvia, Lopez, Hugo, Gutierrez, Madelyn, Langbaum, Jessica B, Cho, William, Suliman, Shehnaaz, Tariot, Pierre N, Ho, Carole, Reiman, Eric M, and Lopera, Francisco

Subjects
Adult, Alzheimer Disease, Child, Colombia, Female, Homozygote, Humans, Male, Middle Aged, Mutation, Presenilin-1, Clinical Sciences, Neurosciences, Cognitive Sciences, Neurology & Neurosurgery
Published
2015

16. The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease

Author

Lopez Lopez, Cristina, Tariot, Pierre N., Caputo, Angelika, Langbaum, Jessica B., Liu, Fonda, Riviere, Marie-Emmanuelle, Langlois, Carolyn, Rouzade-Dominguez, Marie-Laure, Zalesak, Martin, Hendrix, Suzanne, Thomas, Ronald G., Viglietta, Vissia, Lenz, Rob, Ryan, J. Michael, Graf, Ana, and Reiman, Eric M.

Published
2019
Full Text
View/download PDF

17. Brain imaging measurements of fibrillar amyloid-β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele

Author

Ghisays, Valentina, Goradia, Dhruman D., Protas, Hillary, Bauer, Robert J., III, Devadas, Vivek, Tariot, Pierre N., Lowe, Val J., Knopman, David S., Petersen, Ronald C., Jack, Clifford R., Jr., Caselli, Richard J., Su, Yi, Chen, Kewei, and Reiman, Eric M.

Published
2019
Full Text
View/download PDF

18. Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes

Author

Riviere, Marie‐Emmanuelle, primary, Langbaum, Jessica B., additional, Turner, R. Scott, additional, Rinne, Juha O., additional, Sui, Yihan, additional, Cazorla, Pilar, additional, Ricart, Javier, additional, Meneses, Kathleen, additional, Caputo, Angelika, additional, Tariot, Pierre N., additional, Reiman, Eric M., additional, and Graf, Ana, additional

Published
2023
Full Text
View/download PDF

19. Informed consent process experience in Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease Colombia trial

Author

Ríos‐Romenets, Silvia, primary, Giraldo‐Chica, Margarita M., additional, Gutierrez, Madelyn, additional, Acosta‐Baena, Natalia, additional, Espinosa, Alejandro, additional, Quiroz, Yakeel T., additional, Ruiz, Alejandra, additional, Giraldo, Andrea, additional, Langbaum, Jessica B., additional, Cho, William, additional, Reiman, Eric M., additional, Tariot, Pierre N., additional, and Lopera, Francisco, additional

Published
2023
Full Text
View/download PDF

20. Contraception in Female Volunteer in Alzheimer’s Prevention Initiative Autosomal‐dominant Alzheimer’s disease Colombia Trial, a Phase II Clinical Trial to Test Safety and Efficacy of Crenezumab

Author

Martínez, Juan F, primary, Bustamante, Christian, additional, Navarro, Alexander, additional, Lopera, Margarita M, additional, Villegas, Gustavo, additional, Acosta‐Baena, Natalia, additional, Duque, Sindy, additional, Tariot, Pierre N., additional, Langbaum, Jessica B., additional, Ríos‐Romenets, Silvia, additional, and Lopera, Francisco, additional

Published
2023
Full Text
View/download PDF

21. Effect of Age Range on Power for a Clinical Trial Investigating the Effect of Intensive Systolic Blood Pressure Control on White Matter Hyperintensity Volume Accumulation

Author

Pruzin, Jeremy J., primary, Chen, Yinghua, additional, Chen, Kewei, additional, Koijs, Daniel, additional, Newby, Danielle, additional, Winchester, Laura M, additional, Thomas, Ronald G., additional, McGrath, Emer R, additional, Su, Yi, additional, Reboussin, David M., additional, Pajewski, Nicholas M., additional, Beiser, Alexa S., additional, Seshadri, Sudha, additional, and Tariot, Pierre N., additional

Published
2023
Full Text
View/download PDF

22. Statistical innovations in the API ADAD Colombia trial: a randomized, double‐blind, placebo‐controlled, parallel‐group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab

Author

Hu, Nan, primary, Mackey, Howard, additional, Doody, Rachelle S., additional, Lopera, Francisco, additional, Tariot, Pierre N., additional, Reiman, Eric M., additional, Thomas, Ronald G., additional, Langbaum, Jessica B., additional, and Sink, Kaycee M., additional

Published
2023
Full Text
View/download PDF

23. The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort

Author

Tariot, Pierre N., Lopera, Francisco, Langbaum, Jessica B., Thomas, Ronald G., Hendrix, Suzanne, Schneider, Lon S., Rios-Romenets, Silvia, Giraldo, Margarita, Acosta, Natalia, Tobon, Carlos, Ramos, Claudia, Espinosa, Alejandro, Cho, William, Ward, Michael, Clayton, David, Friesenhahn, Michael, Mackey, Howard, Honigberg, Lee, Sanabria Bohorquez, Sandra, Chen, Kewei, Walsh, Trisha, Langlois, Carolyn, and Reiman, Eric M.

Published
2018
Full Text
View/download PDF

24. Psychological Status of the Participants in Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer’s Disease Colombia

Author

Ramos, Claudia, primary, Madrigal, Claudia, additional, Aguirre-Acevedo, Daniel Camilo, additional, Giraldo-Chica, Margarita, additional, Acosta-Baena, Natalia, additional, Aponte, Claudia, additional, Aguillón, David, additional, Gómez, Manuela, additional, Espinosa, Alejandro, additional, Madrigal, Lucia, additional, Uribe, Claramonika, additional, Saldarriaga, Amanda, additional, Alzate, Diana, additional, Ruiz, Alejandra, additional, Andrade, Angela, additional, Lopez, Hugo, additional, Langbaum, Jessica B., additional, Sink, Kaycee M., additional, Reiman, Eric M., additional, Tariot, Pierre N., additional, Ríos-Romenets, Silvia, additional, and Lopera, Francisco, additional

Published
2023
Full Text
View/download PDF

26. Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes.

Author

Riviere, Marie‐Emmanuelle, Langbaum, Jessica B., Turner, R. Scott, Rinne, Juha O., Sui, Yihan, Cazorla, Pilar, Ricart, Javier, Meneses, Kathleen, Caputo, Angelika, Tariot, Pierre N., Reiman, Eric M., and Graf, Ana

Abstract

INTRODUCTION: Alzheimer's Prevention Initiative Generation Study 1 evaluated amyloid beta (Aβ) active immunotherapy (vaccine) CAD106 and BACE‐1 inhibitor umibecestat in cognitively unimpaired 60‐ to 75‐year‐old participants at genetic risk for Alzheimer's disease (AD). The study was reduced in size and terminated early. Results from the CAD106 cohort are presented. METHODS: Sixty‐five apolipoprotein E ε4 homozygotes with/without amyloid deposition received intramuscular CAD106 450 μg (n = 42) or placebo (n = 23) at baseline; Weeks 1, 7, 13; and quarterly; 51 of them had follow‐up Aβ positron emission tomography (PET) scans at 18 to 24 months. RESULTS: CAD106 induced measurable serum Aβ immunoglobulin G titers in 41/42 participants, slower rates of Aβ plaque accumulation (mean [standard deviation] annualized change from baseline in amyloid PET Centiloid: −0.91[5.65] for CAD106 versus 8.36 [6.68] for placebo; P < 0.001), and three amyloid‐related imaging abnormality cases (one symptomatic). DISCUSSION: Despite early termination, these findings support the potential value of conducting larger prevention trials of Aβ active immunotherapies in individuals at risk for AD. Highlights: This was the first amyloid‐lowering prevention trial in persons at genetic risk of late‐onset Alzheimer's disease (AD).Active immunotherapy targeting amyloid (CAD106) was tested in this prevention trial.CAD106 significantly slowed down amyloid plaque deposition in apolipoprotein E homozygotes.CAD106 was generally safe and well tolerated, with only three amyloid‐related imaging abnormality cases (one symptomatic).Such an approach deserves further evaluation in larger AD prevention trials. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Sex differences in blood biomarkers and cognitive performance in individuals with autosomal dominant Alzheimer's disease

Author

Vila‐Castelar, Clara, primary, Chen, Yinghua, additional, Langella, Stephanie, additional, Lopera, Francisco, additional, Zetterberg, Henrik, additional, Hansson, Oskar, additional, Dage, Jeffrey L., additional, Janelidzde, Shorena, additional, Su, Yi, additional, Chen, Kewei, additional, Pluim McDowell, Celina, additional, Martinez, Jairo E., additional, Ramirez‐Gomez, Liliana, additional, Garcia, Gloria, additional, Aguillon, David, additional, Baena, Ana, additional, Giraldo‐Chica, Margarita, additional, Protas, Hillary D., additional, Ghisays, Valentina, additional, Rios‐Romenets, Silvia, additional, Tariot, Pierre N., additional, Blennow, Kaj, additional, Reiman, Eric M., additional, and Quiroz, Yakeel T., additional

Published
2023
Full Text
View/download PDF

30. Additional file 1 of Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease

Author

Caputo, Angelika, Racine, Amy, Paule, Ines, Tariot, Pierre N., Langbaum, Jessica B., Coello, Neva, Riviere, Marie-Emmanuelle, Ryan, J. Michael, Lopez, Cristina Lopez, and Graf, Ana

Abstract

Additional file 1: Supplemental material. Fig. S1. Cognitive composites over time by genotype: individual time profiles and LOESS estimates for progressors to dementia. Fig. S2. Cross validation of TTE model structure. Fig. S3. Model diagnostic of the APCC model for non-progressors (VPC).

Published
2023
Full Text
View/download PDF

31. A Public Resource of Baseline Data from the Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer’s Disease Trial

Author

Reiman, Eric M., Pruzin, Jeremy J., Rios-Romenets, Silvia, Brown, Chris, Giraldo, Margarita, Acosta-Baena, Natalia, Tobon, Carlos, Hu, Nan, Chen, Yinghua, Ghisays, Valentina, Enos, Jessica, Goradia, Dhruman D., Lee, Wendy, Luo, Ji, Malek-Ahmadi, Michael, Protas, Hillary, Thomas, Ronald G., Chen, Kewei, Su, Yi, Boker, Connie, Mastroeni, Diego, Alvarez, Sergio, Quiroz, Yakeel T., Langbaum, Jessica B., Sink, Kaycee M., Lopera, Francisco, and Tariot, Pierre N.

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Geriatrics and Gerontology, Article
Abstract

The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease (API ADAD) Trial evaluated the anti-oligomeric amyloid beta (Aβ) antibody therapy crenezumab in cognitively unimpaired members of the Colombian presenilin 1 (PSEN1) E280A kindred. We report availability, methods employed to protect confidentiality and anonymity of participants, and process for requesting and accessing baseline data.We developed mechanisms to share baseline data from the API ADAD Trial in consultation with experts and other groups sharing data from Alzheimer's disease (AD) prevention trials, balancing the need to protect anonymity and trial integrity with making data broadly available to accelerate progress in the field. We pressure-tested deliberate and inadvertent potential threats under specific assumptions, employed a system to suppress or mask both direct and indirect identifying variables, limited and firewalled data managers, and put forth specific principles requisite to receive data.Baseline demographic, PSEN1 E280A and apolipoprotein E genotypes, florbetapir and fluorodeoxyglucose positron emission tomography, magnetic resonance imaging, clinical, and cognitive data can now be requested by interested researchers.Baseline data are publicly available; treatment data and biological samples, including baseline and treatment-related blood-based biomarker data will become available in accordance with our original trial agreement and subsequently developed Collaboration for Alzheimer's Prevention principles. Sharing of these data will allow exploration of important questions including the differential effects of initiating an investigational AD prevention therapy both before as well as after measurable Aβ plaque deposition.

Published
2022

32. Reproductive health data and its relationship to baseline brain imaging and cognitive measurements in cognitively unimpaired female PSEN1 E280A mutation carriers and non‐carriers from the API ADAD Trial

Author

Ghisays, Valentina, primary, Vila‐Castelar, Clara, additional, Giraldo‐Chica, Margarita, additional, Acosta‐Baena, Natalia, additional, Protas, Hillary D., additional, Malek‐Ahmadi, Michael H., additional, Chen, Yinghua, additional, Luo, Ji, additional, Lee, Wendy, additional, Bocanegra, Yamile, additional, Muñoz, Claudia, additional, Herrera, Karina, additional, Hu, Nan, additional, Sink, Kaycee M., additional, Clayton, David, additional, Alvarez, Sergio, additional, Langbaum, Jessica B., additional, Chen, Kewei, additional, Su, Yi, additional, Tariot, Pierre N., additional, Quiroz, Yakeel T., additional, Lopera, Francisco, additional, Reiman, Eric M., additional, Ríos‐Romenets, Silvia, additional, and Group, API ADAD Colombia Trial, additional

Published
2022
Full Text
View/download PDF

33. APOE ε4 and global cognitive functioning in individuals with autosomal dominant Alzheimer’s disease due to the PSEN1 E280A variant

Author

Vasquez, Daniel, primary, Aguillon, David, additional, Chen, Yinghua, additional, Su, Yi, additional, Quintero, Juan Felipe, additional, Acosta‐Baena, Natalia, additional, Acosta‐Uribe, Juliana, additional, Baena, Ana Y., additional, Garcia, Gloria, additional, Guzman, Claudia F, additional, Giraldo‐Chica, Margarita, additional, Tirado, Victoria, additional, Muñoz, Claudia, additional, Ríos‐Romenets, Silvia, additional, Oliveira, Gabriel, additional, Langella, Stephanie, additional, Yang, Hyun‐Sik, additional, Vila‐Castelar, Clara, additional, Pruzin, Jeremy J., additional, Ghisays, Valentina, additional, Tariot, Pierre N., additional, Arboleda‐Velasquez, Joseph F, additional, Kosik, Kenneth S., additional, Reiman, Eric M., additional, Lopera, Francisco, additional, and Quiroz, Yakeel T., additional

Published
2022
Full Text
View/download PDF

36. Efficacy and safety of pimavanserin in patients with Alzheimer’s dementia psychosis in the HARMONY phase 3, randomized discontinuation study: a post hoc subgroup analysis

Author

Cummings, Jeffrey, primary, Devanand, Davangere P, additional, Ballard, Clive G, additional, Tariot, Pierre N., additional, Hendrix, Suzanne B., additional, Dickson, Samuel P., additional, Li, Caiyan, additional, Abler, Victor, additional, Pathak, Sanjeev, additional, and Stankovic, Srdjan, additional

Published
2022
Full Text
View/download PDF

37. Clinical Profiles of Persons Who Progress to Cognitive Impairment in the Alzheimer’s Prevention Initiative (API) ADAD Colombia Trial

Author

Giraldo‐Chica, Margarita, primary, Acosta‐Baena, Natalia, additional, Espinosa, Alejandro, additional, Ramos, Claudia, additional, Langbaum, Jessica B., additional, Sink, Kaycee M., additional, Tariot, Pierre N., additional, Reiman, Eric M., additional, Lopera, Francisco, additional, and Ríos‐Romenets, Silvia, additional

Published
2022
Full Text
View/download PDF

38. Effect of APOE4 on Plasma Phospho‐tau 217 and Neurofilament Light in the PSEN1 E280A Autosomal Dominant Alzheimer’s Disease Colombian Kindred

Author

Pruzin, Jeremy J., primary, Su, Yi, additional, Chen, Yinghua, additional, Chen, Kewei, additional, Lopez, Hugo, additional, Acosta‐Uribe, Juliana, additional, Alzate, Diana, additional, Aguillon, David, additional, Garcia, Gloria, additional, Craig‐Mueller, Jennifer, additional, Serrano, Geidy E, additional, Langbaum, Jessica B., additional, Ríos‐Romenets, Silvia, additional, Quiroz, Yakeel T., additional, Dage, Jeffrey L., additional, Hansson, Oskar, additional, Blennow, Kaj, additional, Zetterberg, Henrik, additional, Kosik, Kenneth S., additional, Lopera, Francisco, additional, Tariot, Pierre N., additional, and Reiman, Eric M., additional

Published
2022
Full Text
View/download PDF

39. Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease

Author

Caputo, Angelika, primary, Racine, Amy, additional, Paule, Ines, additional, Tariot, Pierre N., additional, Langbaum, Jessica B., additional, Coello, Neva, additional, Riviere, Marie-Emmanuelle, additional, Ryan, J. Michael, additional, Lopez, Cristina Lopez, additional, and Graf, Ana, additional

Published
2022
Full Text
View/download PDF

46. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study

Author

Reiman, Eric M, Quiroz, Yakeel T, Fleisher, Adam S, Chen, Kewei, Velez-Pardo, Carlos, Jimenez-Del-Rio, Marlene, Fagan, Anne M, Shah, Aarti R, Alvarez, Sergio, Arbelaez, Andrés, Giraldo, Margarita, Acosta-Baena, Natalia, Sperling, Reisa A, Dickerson, Brad, Stern, Chantal E, Tirado, Victoria, Munoz, Claudia, Reiman, Rebecca A, Huentelman, Matthew J, Alexander, Gene E, Langbaum, Jessica BS, Kosik, Kenneth S, Tariot, Pierre N, and Lopera, Francisco

Published
2012
Full Text
View/download PDF

47. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study

Author

Fleisher, Adam S, Chen, Kewei, Quiroz, Yakeel T, Jakimovich, Laura J, Gomez, Madelyn Gutierrez, Langois, Carolyn M, Langbaum, Jessica BS, Ayutyanont, Napatkamon, Roontiva, Auttawut, Thiyyagura, Pradeep, Lee, Wendy, Mo, Hua, Lopez, Liliana, Moreno, Sonia, Acosta-Baena, Natalia, Giraldo, Margarita, Garcia, Gloria, Reiman, Rebecca A, Huentelman, Matthew J, Kosik, Kenneth S, Tariot, Pierre N, Lopera, Francisco, and Reiman, Eric M

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results